Anti-TMPRSS6 Monoclonal Antibody DISC-3405 clinical trials
Also written DISC-3405.
How each study uses Anti-TMPRSS6 Monoclonal Antibody DISC-3405 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-TMPRSS6 Monoclonal Antibody DISC-3405 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Disc Medicine, Inc (3) · Mabwell (Shanghai) Bioscience Co., Ltd. (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Anti-TMPRSS6 Monoclonal Antibody DISC-3405.
- Jun 2027A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)Phase 1 · Disc Medicine, Inc
- Jul 2027A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)Phase 2 · Disc Medicine, Inc
Studies
Open first, then newest update. How each study uses Anti-TMPRSS6 Monoclonal Antibody DISC-3405 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)RecruitingPhase 1Disc Medicine, IncNCT07187973Written as DISC-3405
- A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia VeraRecruitingPhase 1Mabwell (Shanghai) Bioscience Co., Ltd.NCT06752746Written as 9MW3011
- A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemiaRecruitingPhase 1Mabwell (Shanghai) Bioscience Co., Ltd.NCT06772766Written as 9MW3011
- A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)Active, not recruitingPhase 2Disc Medicine, IncNCT06985147Written as DISC-3405
- Single Ascending Dose Study of 9MW3011 in Chinese Healthy SubjectCompletedPhase 1Mabwell (Shanghai) Bioscience Co., Ltd.NCT06389942Written as 9MW3011
- A Study of DISC-3405 in Healthy VolunteersCompletedPhase 1Disc Medicine, IncNCT06050915Written as DISC-3405